+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Abuse Deterrent Formulation Technologies Market, 2019-2030

  • ID: 4846375
  • Report
  • 280 Pages
  • Roots Analysis
1 of 5

FEATURED COMPANIES

  • Acella Pharmaceuticals
  • Capsugel
  • Encap Drug Delivery
  • inVentiv Health
  • New River Pharmaceuticals
  • Relmada Therapeutics
  • MORE

Although the healthcare industry relies on the patient to take medications responsibly, in 2017, close to 18 million individuals were reported to have misused prescription drugs, in the US. In fact, data from a National Survey on Drug Use and Health conducted in the same year showed that an estimated 2 million Americans misused prescription pain relievers for the first time in the previous year. Moreover, the same study reported 1.5 million people abusing tranquilizers, over 1 million abusing prescription stimulants and more than 270,000 abusing sedatives, for the first time, in the same time period.

Owing to a rapid onset of the medicinal effect, which offers immediate relief (with high efficacy), opioids are still considered to be one of the most widely used pharmacological interventions for pain management. However, these drugs are known to induce a euphoric state upon consumption, often causing patients to abuse them; increased recreational use of opioids is known to lead to addiction. Moreover, over-prescription of such medicinal products, which promotes their misuse, is considered as one of the root causes of the opioid crisis (increasing number of deaths involving misuse and addiction to opioids), in the US. According to the Centers for Disease Control and Prevention (CDC), more than 72,000 overdose-related deaths were reported in 2017, of which close to 50,000 involved the use of an opioid. Moreover, opioid abuse was estimated to have been responsible for an economic deficit of over USD 500 billion, related to loss of productivity and healthcare costs, in the US. Other drug classes that are prone to abuse include antidepressants and central nervous system (CNS) stimulants. In 2017, close to 17,000 deaths were reported to have been the result of an overdose of prescription antidepressants. Most of these deaths (~11,500) involved the misuse of benzodiazepines, such as VALIUM® (diazepam) and XANAX® (alprazolam). CNS stimulants are usually indicated for the treatment of patients suffering from attention-deficit / hyperactivity disorder (ADHD). Among the various overdose-related deaths which took place in 2017, it is worth highlighting that over 12% involved the use of psychostimulants.

Prescription drug abuse has prompted pharmaceutical developers to devise various strategies to prevent misuse. Some of the commonly used approaches to abuse deterrence include limiting the use of opioids post-surgery, implementing stringent medicine prescribing guidelines and conducting prescription drug monitoring programs, and creating abuse-deterrent formulations (ADFs) of drugs that are likely to be misused. Drug formulations that are designed to prevent an active pharmacological substance from being abused have been identified as a viable and sustainable alternative to limiting recreational / off-prescription use of the abovementioned drug classes and its consequences. Over the years, several different types of abuse-deterrent formulation technologies have been developed; these include physical/chemical barriers that prevent drugs from being manipulated for recreational use, the addition of chemical agents that interfere with the effects of the drug upon improper use and abuse-resistant drug delivery/administration technologies. Specifically, for opioids, market experts believe that in the foreseen future, ADFs of such drugs are likely to replace conventional forms of such products. However, there are concerns regarding how this transition can be made in a responsible and economically feasible manner.

Scope of the Report

The 'Abuse-Deterrent Formulation Technologies Market, 2019-2030' report features an extensive study of the current market landscape and the future potential of industry players that are offering various abuse-deterrent formulation technologies to different pharmaceutical companies. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of companies offering technologies for the development of abuse-deterrent formulations of prescription drugs that are prone to be misused, including information on key technology developers (such as year of establishment, company size, and geographical location), and their respective technologies, offering insights on current status of development (available for use and under development), target drug class (opioids, antidepressants and CNS stimulants), abuse deterrence approach (physical and chemical barriers, prodrug approach, use of agonist / antagonist, aversion, use of specific drug delivery systems, and others), disrupted route of abuse (parenteral, insufflation, covert administration, oral, and others), type of end product (tablets, capsules, transdermal patches, thin films, and others), and release characteristics (delayed / extended, controlled, immediate, and others).
  • An informed competitiveness analysis of the various abuse-deterrent drug formulation technologies captured in our database, taking into consideration the supplier power (based on year of establishment) and key technology-related specifications, such as the abuse-deterrent approach, disrupted route of abuse, number of products available / under development using a particular technology and strength of intellectual property portfolio (in terms of number of affiliated patents).
  • Elaborate profiles of prominent technology developers engaged in this domain, featuring an overview of the company, its financial information (if available), and a detailed description of proprietary technology/technologies. Each profile also includes a list of recent developments, highlighting the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
  • An in-depth analysis of the patents that have been filed/granted related to abuse-deterrent formulation technologies, from 2000 to 2019 (till April). The analysis also highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading patent assignees (in terms of the number of patents filed/granted), and patent benchmarking.
  • An analysis of the partnerships that have been established in the domain in the period 2013-2019, covering product commercialization and licensing agreements, product development agreements, licensing agreements, mergers/acquisitions, service agreements, research agreements, and others.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on likely licensing deal structures and agreements that are expected to be signed between drug and technology developers in the foreseen future, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030. The report features likely distribution of the current and forecasted financial opportunity across [A] target drug class (opioids, antidepressants and CNS stimulants), [B] abuse deterrence approach (physical / chemical barriers, agonist / antagonist combinations, aversion approach, prodrug approach, abuse-deterrent drug delivery systems and others),  [C] type of end product (tablets, capsules, transdermal patches, thin films and others), and [D] geography (North America, Europe, Asia Pacific and the rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Greg Sturmer (President and Chief Executive Officer, Elysium Therapeutics)
  • Aia Malik (Commercial Development Manager, Healthcare, Lucideon)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acella Pharmaceuticals
  • Capsugel
  • Encap Drug Delivery
  • inVentiv Health
  • New River Pharmaceuticals
  • Relmada Therapeutics
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Prescription Drug Abuse / Misuse
3.3. Commonly Abused Drug Classes
3.3.1. Opioids
3.3.2. Antidepressants
3.3.3. Central Nervous System (CNS) Stimulants
3.4. Preliminary Strategies to Prevent Abuse
3.4.1. Role of Healthcare Authorities / Policy Makers
3.4.2. Role of Pharmacists
3.4.3. Role of Clinicians
3.4.4. Role of Patients
3.5. Abuse Deterrent Formulations and Affiliated Technologies
3.5.1. Types of Abuse Deterrent Formulation Approaches
3.5.1.1. Physical and Chemical Barriers
3.5.1.2. Prodrug Approach
3.5.1.3. Chemical Agonists / Antagonists
3.5.1.4. Aversion
3.5.1.5. Drug Delivery Systems
3.5.1.6. Others
3.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Abuse Deterrent Formulation Technologies: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location
4.2.4. Analysis by Status of Development
4.2.5. Analysis by Target Drug Class
4.2.6. Analysis by Abuse Deterrence Approach
4.2.7. Analysis by Disrupted Route of Abuse
4.2.8. Analysis by Type of End Product
4.2.9. Analysis by Release Characteristics

5. COMPETITIVENESS ANALYSIS OF TECHNOLOGY PLATFORMS
5.1. Chapter Overview
5.2. Methodology
5.2.1. Assumptions and Key Parameters
5.3. Platform Competitiveness Analysis
5.3.1. Technologies Developed by Small-sized Companies
5.3.2. Technologies Developed by Mid-sized Companies
5.3.3. Technologies Developed by Large Companies
5.3.4. Technologies Developed by Very Large Companies

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Acura Pharmaceuticals
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Technology Overview
6.2.3.1. AVERSION®
6.2.3.2. IMPEDE®
6.2.3.3. LIMITX™
6.2.4. Recent Developments and Future Outlook
6.3. Altus Formulation
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Technology Overview
6.3.3.1. INTELLITAB™
6.3.4. Recent Developments and Future Outlook
6.4. BioDelivery Sciences International
6.4.1. Company Overview
6.4.2. Technology Overview
6.4.2.1. BEMA®Technology
6.4.3. Recent Developments and Future Outlook
6.5. CIMA LABS (acquired by Teva Pharmaceutical)
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Technology Overview
6.5.3.1. OraGuard™ Technology
6.5.4. Recent Developments and Future Outlook
6.6. Elysium Therapeutics
6.6.1. Company Overview
6.6.2. Technology Overview
6.6.2.1. XpiRx™ Technology
6.6.2.2. O2P™
6.6.3. Recent Developments and Future Outlook
6.7. Grünenthal
6.7.1. Company Overview
6.7.2. Technology Overview
6.7.2.1. INTAC®
6.7.3. Recent Developments and Future Outlook
6.8. Intellipharmaceutics
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Technology Overview
6.8.3.1. nPODDDS™
6.8.3.2. PODRAS™
6.8.3.3. IntelliPaste™
6.8.4. Recent Developments and Future Outlook
6.9. Purdue Pharma
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Technology Overview
6.9.3.1. RESISTEC™
6.9.4. Recent Developments and Future Outlook
6.10. TITAN Pharmaceuticals
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Technology Overview
6.10.3.1. ProNeura™ Drug Delivery Platform
6.10.4. Recent Developments and Future Outlook

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Abuse Deterrent Formulation Technologies: Analysis of Patent Portfolio
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Issuing Authority / Patent Offices Involved
7.3.3. Analysis by CPC Classification
7.3.4. Analysis by Patent Age
7.3.5. Emerging Focus Areas
7.3.6. Leading Industry Players: Analysis by Number of Patents
7.4. Abuse-Deterrent Formulation Technologies: Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics

8. RECENT PARTNERSHIPS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Abuse-Deterrent Formulation Technologies: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Partner
8.3.5. Analysis by Year and Type of Partner
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Regional Analysis
8.3.7.1. Intercontinental and Intracontinental Agreements

9. LIKELY DRUG CANDIDATES FOR DEVELOPMENT OF ABUSE DETERRENT ALTERNATIVES
9.1. Chapter Overview
9.2. Likely Candidates for ADFs: Opioids
9.3. Likely Candidates for ADFs: Antidepressants
9.4. Likely Candidates for ADFs: CNS Stimulants
9.5. Concluding Remarks

10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Abuse-Deterrent Technologies Market, 2019-2030
10.4. Abuse-Deterrent Technologies Market: Distribution by Upfront and Milestone Payments, 2019-2030
10.5. Abuse Deterrent Technologies Market: Distribution by Drug Class, 2019-2030
10.5.1. Abuse Deterrent Technologies Market for Opioids, 2019-2030
10.5.2. Abuse Deterrent Technologies Market for Antidepressants, 2019-2030
10.5.3. Abuse Deterrent Technologies Market for CNS Stimulants, 2019-2030
10.6. Abuse Deterrent Technologies Market: Distribution by Abuse Deterrence Approach, 2019-2030
10.6.1. Abuse Deterrent Technologies Market for Physical / Chemical Barriers, 2019-2030
10.6.2. Abuse Deterrent Technologies Market for Agonist / Antagonist Combinations, 2019-2030
10.6.3. Abuse Deterrent Technologies Market for Aversion Approach, 2019-2030
10.6.4. Abuse Deterrent Technologies Market for Prodrug Approach, 2019-2030
10.6.5. Abuse Deterrent Technologies Market for Abuse Deterrent Drug Delivery Systems, 2019-2030
10.6.6. Abuse Deterrent Market for Other Approaches, 2019-2030
10.7. Abuse Deterrent Technologies Market: Distribution by Type of End Product, 2019-2030
10.7.1. Abuse Deterrent Technologies Market for Tablets, 2019-2030
10.7.2. Abuse Deterrent Technologies Market for Capsules, 2019-2030
10.7.3. Abuse Deterrent Technologies Market for Transdermal Patches, 2019-2030
10.7.4. Abuse Deterrent Technologies Market for Thin Films, 2019-2030
10.7.5. Abuse Deterrent Technologies Market for Other Types of End Products, 2019-2030
10.8. Abuse Deterrent Technologies Market: Geographical Distribution, 2019-2030
10.8.1. Abuse Deterrent Technologies Market in North America, 2019-2030
10.8.2. Abuse Deterrent Technologies Market in Europe, 2019-2030
10.8.3. Abuse Deterrent Technologies Market in Asia-Pacific and Rest of the World, 2019-2030
10.9. Concluding Remarks

11. CONCLUSION

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Elysium Therapeutics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Greg Sturmer, Chief Executive Officer
12.3. Lucideon
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Aia Malik, Commercial Development Manager, Healthcare

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Commonly Abused Drug Classes
Figure 3.2 Abuse Deterrent Drug Formulation Technologies
Figure 3.3 Abuse Deterrent Formulations based on Physical and Chemical Barrier Approach
Figure 3.4 Abuse Deterrent Formulations based on Prodrug Approach
Figure 3.5 Abuse Deterrent Formulations based on Use of Chemical Agonists and Antagonists
Figure 3.6 Abuse Deterrent Formulations based on Aversion Approach
Figure 3.7 Abuse Deterrent Drug Delivery Systems
Figure 4.1 Abuse Deterrent Formulation Technologies: Distribution by Year of Establishment
Figure 4.2 Abuse Deterrent Formulation Technologies: Distribution by Company Size
Figure 4.3 Abuse Deterrent Formulation Technologies: Distribution by Geographical Location
Figure 4.4 Abuse Deterrent Formulation Technologies: Distribution by Status of Development
Figure 4.5 Abuse Deterrent Formulation Technologies: Distribution by Target Drug Class
Figure 4.6 Abuse Deterrent Formulation Technologies: Distribution by Target Drug Class and Geographical Location
Figure 4.7 Abuse Deterrent Formulation Technologies: Distribution by Abuse Deterrence Approach
Figure 4.8 Abuse Deterrent Formulation Technologies: Distribution by Abuse Deterrence Approach and Target Drug Class
Figure 4.9 Abuse Deterrent Formulation Technologies: Distribution by Abuse Deterrence Approach and Geographical Location
Figure 4.10 Abuse Deterrent Formulation Technologies: Distribution by Disrupted Route of Abuse
Figure 4.11 Abuse Deterrent Formulation Technologies: Distribution by Disrupted Route of Abuse and Geographical Location
Figure 4.12 Abuse Deterrent Formulation Technologies: Distribution by Type of End Product
Figure 4.13 Abuse Deterrent Formulation Technologies: Distribution by Release Characteristics
Figure 4.14 Abuse Deterrent Formulation Technologies: Distribution by Release Characteristics and Target Drug Class
Figure 5.1 Platform Competitiveness Analysis: Technologies Developed by Small-sized Companies
Figure 5.2 Platform Competitiveness Analysis: Technologies Developed by Mid-sized Companies
Figure 5.3 Platform Competitiveness Analysis: Technologies Developed by Large Companies
Figure 5.4 Platform Competitiveness Analysis: Technologies Developed by Very Large Companies
Figure 6.1 Acura Pharmaceuticals: Annual Revenues, 2014-2018 (USD Million)
Figure 6.2 Altus Formulation: Annual Revenues, 2014-2018 (USD Million)
Figure 6.3 CIMA LABS: Annual Revenues, 2014-2018 (USD Million)
Figure 6.4 Intellipharmaceutics: Annual Revenues, 2014-2018 (USD Million)
Figure 6.5 Purdue Pharma: Annual Revenues, 2014-2018 (USD Million)
Figure 6.6 TITAN Pharmaceuticals: Annual Revenues, 2014-2018 (USD Million)
Figure 7.1 Patent Portfolio: Distribution by Type of Patent
Figure 7.2 Patent Portfolio: Cumulative Distribution by Publication Year, 2000-2019
Figure 7.3 Patent Portfolio: Distribution by Geographical Location
Figure 7.4 Patent Portfolio: Distribution by CPC Classification
Figure 7.5 Patent Portfolio: Distribution by Patent Age (2000- 2019)
Figure 7.6 Patent Portfolio: Emerging Focus Areas
Figure 7.7 Patent Portfolio: Leading Industry Players in Terms of Numbers of Patents
Figure 7.8 Patent Portfolio: Competitive Benchmarking by Patent Characteristics
Figure 8.1 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2019
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2013-2019)
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Year and Type of Partner (2013-2019)
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Regional Distribution
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1 Licensing Agreements: Distribution of Financial Components
Figure 10.2 Abuse Deterrent Technologies: Overall Market, 2019-2030 (USD Million)
Figure 10.3 Abuse Deterrent Technologies Market: Distribution by Drug Class, 2019-2030 (USD Million)
Figure 10.4 Abuse Deterrent Technologies Market for Opioids, 2019-2030 (USD Million)
Figure 10.5 Abuse Deterrent Technologies Market for Antidepressants, 2019-2030 (USD Million)
Figure 10.6 Abuse Deterrent Technologies Market for CNS Stimulants, 2019-2030 (USD Million)
Figure 10.7 Abuse Deterrent Technologies Market: Distribution by Abuse Deterrence Approach, 2019-2030 (USD Million)
Figure 10.8 Abuse Deterrent Technologies Market for Physical / Chemical Barriers, 2019-2030 (USD Million)
Figure 10.9 Abuse Deterrent Technologies Market for Agonist / Antagonist Combinations, 2019-2030 (USD Million)
Figure 10.10 Abuse Deterrent Technologies Market for Aversion Approach, 2019-2030 (USD Million)
Figure 10.11 Abuse Deterrent Technologies Market for Prodrug Approach, 2019-2030 (USD Million)
Figure 10.12 Abuse Deterrent Technologies Market for Abuse Deterrent Drug Delivery Systems, 2019-2030 (USD Million)
Figure 10.13 Abuse Deterrent Technologies Market for Other Approaches, 2019-2030 (USD Million)
Figure 10.14 Abuse Deterrent Technologies Market: Distribution by Type of End Product, 2019-2030 (USD Million)
Figure 10.15 Abuse Deterrent Technologies Market for Tablets, 2019-2030 (USD Million)
Figure 10.16 Abuse Deterrent Technologies Market for Capsules, 2019-2030 (USD Million)
Figure 10.17 Abuse Deterrent Technologies Market for Transdermal Patches, 2019-2030 (USD Million)
Figure 10.18 Abuse Deterrent Technologies Market for Thin Films, 2019-2030 (USD Million)
Figure 10.19 Abuse Deterrent Technologies Market for Other Types of End Products, 2019-2030 (USD Million)
Figure 10.20 Abuse Deterrent Technologies Market: Geographical Distribution, 2019-2030 (USD Million)
Figure 10.21 Abuse Deterrent Technologies Market in North America, 2019-2030 (USD Million)
Figure 10.22 Abuse Deterrent Technologies Market in Europe, 2019-2030 (USD Million)
Figure 10.23 Abuse Deterrent Technologies Market in Asia Pacific and Rest of the World, 2019-2030 (USD Million)
Figure 11.1 Abuse Deterrent Technologies Market: Forecast Summary, 2019-2030

List of Tables
Table 3.1 Commonly Abused Prescription Opioids
Table 3.2 Commonly Abused Prescription Antidepressants
Table 3.3 Commonly Abused Prescription CNS Stimulants
Table 3.4 List of Approved Abuse Deterrent Formulations
Table 4.1 Abuse Deterrent Formulation Technologies: List of Companies
Table 4.2 Abuse Deterrent Formulation Technologies: Information on Target Drug Class
Table 4.3 Abuse Deterrent Formulation Technologies: Information on Abuse Deterrence Approach
Table 4.4 Abuse Deterrent Formulation Technologies: Information on Disrupted Route of Abuse
Table 6.1 List of Technology Providers Profiled
Table 6.2 Acura Pharmaceuticals: Key Highlights
Table 6.3 Acura Pharmaceuticals: Recent Developments and Future Outlook
Table 6.4 Altus Formulation: Key Highlights
Table 6.5 Altus Formulation: Recent Developments and Future Outlook
Table 6.6 BioDelivery Sciences International: Key Highlights
Table 6.7 BioDelivery Sciences International: Recent Developments and Future Outlook
Table 6.8 CIMA LABS (acquired by Teva Pharmaceutical): Key Highlights
Table 6.9 CIMA LABS (acquired by Teva Pharmaceutical): Recent Developments and Future Outlook
Table 6.10 Elysium Therapeutics: Key Highlights
Table 6.11 Elysium Therapeutics: Recent Developments and Future Outlook
Table 6.12 Grünenthal: Key Highlights
Table 6.13 Grünenthal: Recent Developments and Future Outlook
Table 6.14 Intellipharmaceutics: Key Highlights
Table 6.15 Intellipharmaceutics: Recent Developments and Future Outlook
Table 6.16 Purdue Pharma: Key Highlights
Table 6.17 Purdue Pharma: Recent Developments and Future Outlook
Table 6.18 TITAN Pharmaceuticals: Key Highlights
Table 6.19 TITAN Pharmaceuticals: Recent Developments and Future Outlook
Table 7.1 Definitions: CPC Classification Symbols
Table 7.2 Analysis of Patent Portfolio: Most Popular CPC Classification Symbols
Table 7.3 Analysis of Patent Portfolio: List of Top CPC Classifications
Table 7.4 Analysis of Patent Portfolio: List of Leading Individual Assignees
Table 7.5 Analysis of Patent Portfolio: Benchmarking Summary
Table 8.1 Abuse Deterrent Formulation Technologies: Partnerships and Collaborations, 2013-2019
Table 9.1 Likely Candidates for ADFs: Opioids
Table 9.2 Likely Candidates for ADFs: Antidepressants
Table 9.3 Likely Candidates for ADFs: CNS Stimulants
Table 12.1 Elysium Therapeutics: Company Snapshot
Table 12.3 Lucideon: Company Snapshot
Table 13.1 Abuse Deterrent Formulation Technologies: Distribution by Year of Establishment
Table 13.2 Abuse Deterrent Formulation Technologies: Distribution by Company Size
Table 13.3 Abuse Deterrent Formulation Technologies: Distribution by Geographical Location
Table 13.4 Abuse Deterrent Formulation Technologies: Distribution by Status of Development
Table 13.5 Abuse Deterrent Formulation Technologies: Distribution by Target Drug Class
Table 13.6 Abuse Deterrent Formulation Technologies: Distribution by Target Drug Class and Geographical Location
Table 13.7 Abuse Deterrent Formulation Technologies: Distribution by Abuse Deterrence Approach
Table 13.8 Abuse Deterrent Formulation Technologies: Distribution by Abuse Deterrence Approach and Target Drug Class
Table 13.9 Abuse Deterrent Formulation Technologies: Distribution by Abuse Deterrence Approach and Geographical Location
Table 13.10 Abuse Deterrent Formulation Technologies: Distribution by Disrupted Route of Abuse
Table 13.11 Abuse Deterrent Formulation Technologies: Distribution by Disrupted Route of Abuse and Geographical Location
Table 13.12 Abuse Deterrent Formulation Technologies: Distribution by Type of End Product
Table 13.13 Abuse Deterrent Formulation Technologies: Distribution by Release Characteristics
Table 13.14 Abuse Deterrent Formulation Technologies: Distribution by Release Characteristics and Target Drug Class
Table 13.15 Acura Pharmaceuticals: Annual Revenues, 2014-2018 (USD Million)
Table 13.16 Altus Formulation: Annual Revenues, 2014-2018 (USD Million)
Table 13.17 CIMA LABS: Annual Revenues, 2014-2018 (USD Million)
Table 13.18 Intellipharmaceutics: Annual Revenues, 2014-2018 (USD Million)
Table 13.19 Purdue Pharma: Annual Revenues, 2014-2018 (USD Million)
Table 13.20 TITAN Pharmaceuticals: Annual Revenues, 2014-2018 (USD Million)
Table 13.21 Patent Portfolio: Distribution by Type of Patent
Table 13.22 Patent Portfolio: Cumulative Distribution by Publication Year, 2000-2019
Table 13.23 Patent Portfolio: Distribution by Geographical Location
Table 13.24 Patent Portfolio: Distribution by Patent Age (2000- 2019)
Table 13.25 Patent Portfolio: Leading Industry Players in Terms of Numbers of Patents
Table 13.26 Patent Portfolio: Competitive Benchmarking by Patent Characteristics
Table 13.27 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2019
Table 13.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2013-2019)
Table 13.30 Partnerships and Collaborations: Distribution by Type of Partner
Table 13.31 Partnerships and Collaborations: Distribution by Year and Type of Partner (2013-2019)
Table 13.32 Most Active Players: Distribution by Number of Partnerships
Table 13.33 Partnerships and Collaborations: Regional Distribution
Table 13.34 Abuse Deterrent Technologies: Overall Market, 2019-2030 (USD Million)
Table 13.35 Abuse Deterrent Technologies Market: Distribution by Drug Class, 2019-2030 (USD Million)
Table 13.36 Abuse Deterrent Technologies Market for Opioids, 2019-2030 (USD Million)
Table 13.37 Abuse Deterrent Technologies Market for Antidepressants, 2019-2030 (USD Million)
Table 13.38 Abuse Deterrent Technologies Market for CNS Stimulants, 2019-2030 (USD Million)
Table 13.39 Abuse Deterrent Technologies Market: Distribution by Abuse Deterrence Approach, 2019-2030 (USD Million)
Table 13.40 Abuse Deterrent Technologies Market for Physical / Chemical Barriers, 2019-2030 (USD Million)
Table 13.41 Abuse Deterrent Technologies Market for Agonist / Antagonist Combinations, 2019-2030 (USD Million)
Table 13.42 Abuse Deterrent Technologies Market for Aversion Approach, 2019-2030 (USD Million)
Table 13.43 Abuse Deterrent Technologies Market for Prodrug Approach, 2019-2030 (USD Million)
Table 13.44 Abuse Deterrent Technologies Market for Abuse Deterrent Drug Delivery Systems, 2019-2030 (USD Million)
Table 13.45 Abuse Deterrent Technologies Market for Other Approaches, 2019-2030 (USD Million)
Table 13.46 Abuse Deterrent Technologies Market: Distribution by Type of End Product, 2019-2030 (USD Million)
Table 13.47 Abuse Deterrent Technologies Market for Tablets, 2019-2030 (USD Million)
Table 13.48 Abuse Deterrent Technologies Market for Capsules, 2019-2030 (USD Million)
Table 13.49 Abuse Deterrent Technologies Market for Transdermal Patches, 2019-2030 (USD Million)
Table 13.50 Abuse Deterrent Technologies Market for Thin Films, 2019-2030 (USD Million)
Table 13.51 Abuse Deterrent Technologies Market for Other Types of End Products, 2019-2030 (USD Million)
Table 13.52 Abuse Deterrent Technologies Market: Geographical Distribution, 2019-2030 (USD Million)
Table 13.53 Abuse Deterrent Technologies Market in North America, 2019-2030 (USD Million)
Table 13.54 Abuse Deterrent Technologies Market in Europe, 2019-2030 (USD Million)
Table 13.55 Abuse Deterrent Technologies Market in Asia Pacific and Rest of the World, 2019-2030 (USD Million)
Table 13.56 Abuse Deterrent Technologies Market: Forecast Summary, 2019-2030

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Acella Pharmaceuticals
  • Capsugel
  • Encap Drug Delivery
  • inVentiv Health
  • New River Pharmaceuticals
  • Relmada Therapeutics
  • MORE

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution and adoption of abuse deterrent formulation technologies market in the mid to long term.

Chapter 3 is an introductory chapter that presents a general overview of the different drug classes that are prone to abuse. It features a discussion on various checkpoints that can be implemented at the clinician-, pharmacist- and patient-level to prevent the misuse of prescription drugs. Further, the chapter provides details on the various abuse deterrent drug formulation technologies that have been developed over the last several years, highlighting their respective mechanisms of action and advantages.

Chapter 4 includes information on companies offering technologies for the development of abuse deterrent formulations of prescription drugs that are prone to be misused, including information on key technology developers (such as year of establishment, company size, and geographical location), and their respective technologies, offering insights on current status of development (available for use and under development), target drug class (opioids, antidepressants and CNS stimulants), abuse deterrence approach (physical and chemical barriers, prodrug approach, use of agonist / antagonist, aversion, use of specific drug delivery systems, and others), disrupted route of abuse (parenteral, insufflation, covert administration, oral, and others), type of end product (tablets, capsules, transdermal patches, thin films, and others), and release characteristics (delayed / extended, controlled, immediate, and others).

Chapter 5 is a competitiveness analysis of the various abuse deterrent drug formulation technologies captured in our database, taking into consideration the supplier power (based on year of establishment) and key technology-related specifications, such as the abuse deterrent approach, disrupted route of abuse, number of products available / under development using a particular technology and strength of intellectual property portfolio (in terms of number of affiliated patents).

Chapter 6 includes detailed profiles of key technology developers (shortlisted based on the results of a proprietary competitiveness analysis) engaged in this domain. Each profile includes an overview of the company, its financial information (if available), and a detailed description of proprietary technology/technologies. Company profiles also include a list of recent developments, highlighting the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.

Chapter 7 provides an in-depth analysis of the patents that have been filed/granted related to abuse deterrent formulation technologies, from 2000 to 2019 (till April). The analysis also highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading patent assignees (in terms of the number of patents filed/granted), and patent benchmarking.

Chapter 8 features an elaborate discussion and analysis of the partnerships that have been established in the domain in the period 2013-2019, covering product commercialization and licensing agreements, product development agreements, licensing agreements, mergers/acquisitions, service agreements, research agreements, and others.

Chapter 9 presents a list of drug candidates, across different therapeutic classes (opioids, antidepressants, and CNS stimulants) that are eligible drugs for conversion/reformulation to ADFs in the foreseen future.

Note: Product cover images may vary from those shown
5 of 5
  • 4P Therapeutics (subsidiary of Nutriband)
  • Acella Pharmaceuticals
  • Acura Pharmaceuticals
  • Adello Biologics
  • Aesica Pharmaceuticals
  • Alitair Pharmaceuticals
  • Altus Formulation
  • Aquestive Therapeutics
  • Assertio Therapeutics
  • Atlantic Pharmaceuticals
  • Avadel Pharmaceuticals
  • Bayer
  • BioDelivery Sciences International
  • Buzzz Pharmaceuticals
  • Camargo Pharmaceutical Services
  • Capsugel
  • Cassava Sciences
  • Catalent
  • CIMA LABS (acquired by Teva)
  • Coating Place
  • Collegium Pharmaceutical
  • Currax Pharmaceuticals
  • Daiichi Sankyo
  • DURECT
  • Egalet
  • Elite Pharmaceuticals
  • Elysium Therapeutics
  • Emplicure
  • Encap Drug Delivery
  • Endo Pharmaceuticals
  • Ensysce Biosciences
  • Epic Pharma
  • Ethypharm
  • ExxPharma Therapeutics
  • Genus Lifesciences
  • Glenmark Pharmaceuticals
  • Grünenthal
  • Indivior
  • Inspirion Delivery Sciences
  • Intalere
  • Intellipharmaceutics
  • inVentiv Health
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • Kashiv BioSciences
  • KemPharm
  • KVK Tech
  • Lannett
  • Lonza
  • Lucideon
  • MainPointe Pharmaceuticals
  • Mallinckrodt Pharmaceuticals
  • Memorial Sloan Kettering Cancer Center
  • Mundipharma
  • Nektar Therapeutics
  • Neos Therapeutics
  • New River Pharmaceuticals
  • Nutriband
  • Optum (part of UnitedHealth Group)
  • Orexo
  • Patheon
  • Pernix Therapeutics
  • Pfizer
  • Pop Test
  • Praxis Bioresearch
  • Publicis Touchpoint Solutions
  • Purdue Pharma
  • QRxPharma
  • Quivive Pharma
  • Recipharm
  • Relmada Therapeutics
  • Shionogi
  • Shire
  • Signature Therapeutics
  • Skyepharma
  • SPARC
  • SunGen Pharma
  • Tetra Bio-Pharma
  • Teva Pharmaceutical
  • TITAN Pharmaceuticals
  • Tris Pharma
  • twoXAR
  • University of Nebraska Medical Center
  • Zogenix
Note: Product cover images may vary from those shown
6 of 5

 

 

Loading
LOADING...

Adroll
adroll